Biomedical research at Oslo University Hospital
Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic research, translational research, and clinical research.
Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.
Click here to see hierarchical division and subunit overview
Summary of publications:
Publications (original articles or review articles) published in 2018 from OUS - National Advisory Unit on Late Effects after Cancer Treatment
21 publications found
Is time from diagnosis to radical prostatectomy associated with oncological outcomes?
World J Urol, 37 (8), 1571-1580
DOI 10.1007/s00345-018-2570-6, PubMed 30483947
Factors influencing access to palliative radiotherapy: a Norwegian population-based study
Acta Oncol, 57 (9), 1250-1258
DOI 10.1080/0284186X.2018.1468087, PubMed 29706109
Patient-reported outcomes after treatment for clinically localized prostate cancer: A systematic review and meta-analysis
Cancer Treat Rev, 66, 23-44
DOI 10.1016/j.ctrv.2018.03.005, PubMed 29673922
Physical activity and associations with treatment-induced adverse effects among prostate cancer patients
Support Care Cancer, 27 (3), 1001-1011
DOI 10.1007/s00520-018-4389-5, PubMed 30094728
Targeting Exercise Interventions to Patients With Cancer in Need: An Individual Patient Data Meta-Analysis
J Natl Cancer Inst, 110 (11), 1190-1200
DOI 10.1093/jnci/djy161, PubMed 30299508
Predicting Cardiovascular Disease Among Testicular Cancer Survivors After Modern Cisplatin-based Chemotherapy: Application of the Framingham Risk Score
Clin Genitourin Cancer, 16 (4), e761-e769
DOI 10.1016/j.clgc.2018.01.011, PubMed 29534941
Late adverse outcomes after treatment of testicular cancer
Onkologe, 24 2, S104-S109
Toxicities Associated with Cisplatin-Based Chemotherapy and Radiotherapy in Long-Term Testicular Cancer Survivors
Adv Urol, 2018, 8671832
DOI 10.1155/2018/8671832, PubMed 29670654
18F-FDG PET Response of Skeletal (Bone Marrow and Bone) Involvement After Induction Chemotherapy in Pediatric Hodgkin Lymphoma: Are Specific Response Criteria Required?
J Nucl Med, 59 (10), 1524-1530
DOI 10.2967/jnumed.117.205633, PubMed 29653979
Hearing loss before and after cisplatin-based chemotherapy in testicular cancer survivors: a longitudinal study
Acta Oncol, 57 (8), 1075-1083
DOI 10.1080/0284186X.2018.1433323, PubMed 29384420
Long-term serum platinum changes and their association with cisplatin-related late effects in testicular cancer survivors
Acta Oncol, 57 (10), 1392-1400
DOI 10.1080/0284186X.2018.1473641, PubMed 29775128
ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up
Ann Oncol, 29 (8), 1658-1686
DOI 10.1093/annonc/mdy217, PubMed 30113631
Cumulative Burden of Morbidity Among Testicular Cancer Survivors After Standard Cisplatin-Based Chemotherapy: A Multi-Institutional Study
J Clin Oncol, 36 (15), 1505-1512
DOI 10.1200/JCO.2017.77.0735, PubMed 29617189
Cancer Survivorship in Adults
Recent Results Cancer Res, 210, 123-143
DOI 10.1007/978-3-319-64310-6_8, PubMed 28924683
Long-term neurotoxicity and Raynaud's phenomenon in patients treated with cisplatin-based chemotherapy for malignant ovarian germ cell tumor
Acta Obstet Gynecol Scand, 98 (2), 240-249
DOI 10.1111/aogs.13477, PubMed 30289161
Effects and moderators of exercise on muscle strength, muscle function and aerobic fitness in patients with cancer: a meta-analysis of individual patient data
Br J Sports Med, 53 (13), 812
DOI 10.1136/bjsports-2018-099191, PubMed 30181323
Fertility Among Female Survivors of Childhood, Adolescent, and Young Adult Cancer: Protocol for Two Pan-European Studies (PanCareLIFE)
JMIR Res Protoc, 7 (9), e10824
DOI 10.2196/10824, PubMed 30215599
Genetic variation in gonadal impairment in female survivors of childhood cancer: a PanCareLIFE study protocol
BMC Cancer, 18 (1), 930
DOI 10.1186/s12885-018-4834-3, PubMed 30257669
International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease
Blood, 132 (20), 2115-2124
DOI 10.1182/blood-2018-07-862334, PubMed 30181172
Ten-year survival after High-Dose-Rate Brachytherapy combined with External Beam Radiation Therapy in high-risk prostate cancer: A comparison with the Norwegian SPCG-7 cohort
Radiother Oncol, 132, 211-217
DOI 10.1016/j.radonc.2018.10.013, PubMed 30389241
Clinical and Genetic Risk Factors for Adverse Metabolic Outcomes in North American Testicular Cancer Survivors
J Natl Compr Canc Netw, 16 (3), 257-265
DOI 10.6004/jnccn.2017.7046, PubMed 29523664